


PHARMACEUTICAL 2018

OMEROS CORP Rank 170 of 349







PHARMACEUTICAL 2018

OMEROS CORP Rank 170 of 349



The relative strengths and weaknesses of OMEROS CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of OMEROS CORP compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 217% points. The greatest weakness of OMEROS CORP is the variable Assets, Current, reducing the Economic Capital Ratio by 64% points.

The company's Economic Capital Ratio, given in the ranking table, is -166%, being 112% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	108,372
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	26,307
Liabilities, Non-Current	0
Other Assets	5,835
Other Compr. Net Income	0
Other Expenses	12,108
Other Liabilities	0
Other Net Income	1,444
Property and Equipment	2,121
Research and Development	55,599
Revenues	64,826
Selling, General and Administrative Expense	52,044

Output Variable	Value in 1000 USD
Assets	116,328
Liabilities	26,307
Expenses	119,751
Stockholders Equity	90,021
Net Income	-53,481
Comprehensive Net Income	-53,481
Economic Capital Ratio	-166%